Trial · NCT02411084
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Overall Response at 28 Days | BEGEDINA® (Begelomab) | Complete response | 3 | Participants | |
| Number of Participants With Overall Response at 28 Days | Conventional Second-line Treatment | Complete response | 5 | Participants | |
| Number of Participants With Overall Response at 28 Days | BEGEDINA® (Begelomab) | Stable Disease | 3 | Participants | |
| Number of Participants With Overall Response at 28 Days | Conventional Second-line Treatment | Stable Disease | 3 | Participants | |
| Number of Participants With Overall Response at 28 Days | BEGEDINA® (Begelomab) | Partial Response | 5 | Participants | |
| Number of Participants With Overall Response at 28 Days | Conventional Second-line Treatment | Partial Response | 8 | Participants | |
| Number of Participants With Overall Response at 28 Days | BEGEDINA® (Begelomab) | Progressive disease | 1 | Participants | |
| Number of Participants With Overall Response at 28 Days | Conventional Second-line Treatment | Progressive disease | 1 | Participants | |
| Number of Participants With Overall Survival (OS) up to 180 Days | BEGEDINA® (Begelomab) | Deceased | 13 | Participants | |
| Number of Participants With Overall Survival (OS) up to 180 Days | Conventional Second-line Treatment | Deceased | 8 | Participants | |
| Number of Participants With Overall Survival (OS) up to 180 Days | BEGEDINA® (Begelomab) | Alive | 5 | Participants | |
| Number of Participants With Overall Survival (OS) up to 180 Days | Conventional Second-line Treatment | Alive | 10 | Participants | |
| BEGEDINA Serum Concentrations Pre- and 15 Minutes Post-Infusion | BEGEDINA® (Begelomab) | Day 1 pre-infusion | 0.0 | Full Range 0 to 155 | ng/ml |
| BEGEDINA Serum Concentrations Pre- and 15 Minutes Post-Infusion | BEGEDINA® (Begelomab) | Day 1 post-infusion | 138.6 | Full Range 72 to 1371 | ng/ml |
| BEGEDINA Serum Concentrations Pre- and 15 Minutes Post-Infusion | BEGEDINA® (Begelomab) | Day 5 pre-infusion | 96.4 | Full Range 46 to 1617 | ng/ml |
| BEGEDINA Serum Concentrations Pre- and 15 Minutes Post-Infusion | BEGEDINA® (Begelomab) | Day 5 post-infusion | 591.1 | Full Range 240 to 6880 | ng/ml |
| BEGEDINA Serum Concentrations Pre- and 15 Minutes Post-Infusion | BEGEDINA® (Begelomab) | Day 10 pre-infusion | 6.9 | Full Range 0 to 1356 | ng/ml |
| BEGEDINA Serum Concentrations Pre- and 15 Minutes Post-Infusion | BEGEDINA® (Begelomab) | Day 10 post-infusion | 289.6 | Full Range 127 to 2080 | ng/ml |
| BEGEDINA Serum Concentrations Pre- and 15 Minutes Post-Infusion | BEGEDINA® (Begelomab) | Day 14 pre-infusion | 5.3 | Full Range 0 to 184 | ng/ml |
| BEGEDINA Serum Concentrations Pre- and 15 Minutes Post-Infusion | BEGEDINA® (Begelomab) | Day 14 post-infusion | 240.7 | Full Range 126 to 2154 | ng/ml |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02411084/results